Source-grounded facts extracted from PROTHENA CORP PUBLIC LTD CO's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PROTHENA CORP PUBLIC LTD CO shareholders approved Approval of Compensation of the Company’s Named Executive Officers at the 2026-05-14 meeting.
“The shareholders approved, in a non-binding advisory vote, the compensation of the Company’s executive officers named in the Proxy Statement. For Against Abstain Broker Non-Votes 32,303,076 1,145,400 1,204,899 7,374,142”
PROTHENA CORP PUBLIC LTD CO shareholders approved Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm for 2026 and Authorization of the Board of Directors to Approve the Remuneration of that Auditor at the 2026-05-14 meeting.
“The shareholders ratified, in a non-binding vote, the appointment of KPMG LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026, and authorized, in a binding vote, the Company’s Board of Directors, acting through its Audit Committee, to approve the remuneration of that auditor. For Against Abstain 41,931,718 82,815 12,984”
PROTHENA CORP PUBLIC LTD CO shareholders approved Election of Directors at the 2026-05-14 meeting.
“The shareholders re-elected the following individuals to the Company’s Board of Directors to hold office until no later than the annual general meeting of shareholders in 2029. Nominee For Against Abstain Broker Non-Votes Shane M. Cooke 22,720,769 11,923,467 9,139 7,374,142 Dennis J. Selkoe 25,226,560 9,420,544 6,271 7,374,142”
PROTHENA CORP PUBLIC LTD CO reported financial results for first quarter of 2026.
“On May 7, 2026, Prothena Corporation plc issued a press release announcing its financial results for the first quarter ended March 31, 2026.”
PROTHENA CORP PUBLIC LTD CO announced a restructuring with charges of approximately $16 to $20 million (approximate 63% reduction in its workforce).
“periods will be extended, pursuant to the terms of the option award agreements under which those stock options were granted. The Company expects to recognize approximately $16 to $20 million in total for severance and related benefits for employees laid off under the reduction in workforce and non-cash share-based compensation expense related to the”
David A. Ford was terminated as Chief People Officer at PROTHENA CORP PUBLIC LTD CO.
“On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.”
Carol D. Karp was terminated as Chief Regulatory Officer at PROTHENA CORP PUBLIC LTD CO.
“On June 18, 2025, the Company announced that in connection with the workforce reduction, the employment of Carol D. Karp, the Company’s Chief Regulatory Officer, and David A. Ford, the Company’s Chief People Officer, will terminate effective August 1, 2025.”
Hideki Garren resigned as Chief Medical Officer at PROTHENA CORP PUBLIC LTD CO.
“On September 23, 2024, Hideki Garren, M.D., Ph.D., Chief Medical Officer of Prothena Corporation plc (the “Company”) notified the Company that he is resigning from the Company effective September 27, 2024.”
PROTHENA CORP PUBLIC LTD CO shareholders approved Approval of an Amendment to the Company’s 2018 Long Term Incentive Plan at the 2024-05-14 meeting.
“The shareholders approved the Amendment, which increases the number of ordinary shares available for issuance under the 2018 LTIP by 2,000,000 ordinary shares. For Against Abstain Broker Non-Votes 36,884,712 8,876,141 1,190,001 2,591,833”
PROTHENA CORP PUBLIC LTD CO shareholders approved Approval of Compensation of the Company’s Named Executive Officers at the 2024-05-14 meeting.
“The shareholders approved, in a non-binding advisory vote, the compensation of the Company’s executive officers named in the Proxy Statement. For Against Abstain Broker Non-Votes 45,331,500 425,331 1,194,023 2,591,833”
PROTHENA CORP PUBLIC LTD CO shareholders approved Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm for 2024 and Authorization of the Board of Directors to Approve the Remuneration of that Auditor at the 2024-05-14 meeting.
“The shareholders ratified, in a non-binding vote, the appointment of KPMG LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024, and authorized, in a binding vote, the Company’s Board of Directors, acting through its Audit Committee, to approve the remuneration of that auditor. For Against Abstain 49,433,824 63,084 45,779”
PROTHENA CORP PUBLIC LTD CO shareholders approved Election of Directors at the 2024-05-14 meeting.
“The shareholders re-elected the following individuals to the Company's Board of Directors to hold office until no later than the annual general meeting of shareholders in 2027. Nominee For Against Abstain Broker Non-Votes Richard T. Collier 42,704,695 4,230,920 15,239 2,591,833 Shane M. Cooke 46,538,265 398,049 14,540 2,591,833 William H. Dunn, Jr. 46,769,850 165,930 15,074 2,591,833 Daniel G. Welch 40,327,963 6,608,319 14,572 2,591,833”
PROTHENA CORP PUBLIC LTD CO reported financial results for first quarter ended March 31, 2024.
“On May 8, 2024, Prothena Corporation plc issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
Daniel G. Welch was appointed as Director and Chair Designate at PROTHENA CORP PUBLIC LTD CO.
“On February 21, 2024, the Board of Directors (the “Board”) of Prothena Corporation plc (the “Company”) increased the size of the Board and appointed Daniel G. Welch to serve as a director of the Company, effective immediately.”
PROTHENA CORP PUBLIC LTD CO updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (initiated).
“On February 15, 2024, Prothena Corporation plc issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.”
PROTHENA CORP PUBLIC LTD CO reported third quarter ended September 30, 2023 results: revenue 84.9 million, net income 21.9 million, EPS 0.38.
“Prothena reported net income of $21.9 million and net loss of $79.6 million , respectively, as compared to a net loss o f $45.8 million and $123.3 million for the third quarter and first nine months of 2022, respectively. Net income per share on a diluted basis for the third quarter was $0.38 and net loss per share for the first nine months of 2023 was $1.50 , a s compared to net loss per share of $0.97 and $2.63 f or the third quarter and first nine months of 2022, respectively. Prothena reported total revenue of $84.9 million and $91.1 million for the third quarter and first nine months of 2023, respectively, as compared to total revenue of $1.5 million and $4.0 million for the third quarter and first nine months of 2022”
PROTHENA CORP PUBLIC LTD CO updated its the second quarter ended June 30, 2023 guidance (lowered).
“Prothena Corporation plc issued a press release announcing its financial results for the second quarter ended June 30, 2023.”
PROTHENA CORP PUBLIC LTD CO entered into Tau Global License Agreement with Bristol Myers Squibb valued at $55 million (effective 2023-07-05).
“On July 5, 2023 and pursuant to the option exercised by BMS under the Master Collaboration Agreement, Prothena and BMS entered into a Global License Agreement (the “Tau Global License Agreement”) granting BMS the exclusive license to develop, manufacture and commercialize Tau Collaboration Products globally for any and all uses or purposes with respect to any human or animal disease, disorder or condition.”
PROTHENA CORP PUBLIC LTD CO shareholders approved Approval of an Amendment to the Company’s 2018 Long Term Incentive Plan at the 2023-05-16 meeting.
“Proposal No. 4: Approval of an Amendment to the Company’s 2018 Long Term Incentive Plan. The shareholders approved the Amendment, which increases the number of ordinary shares available for issuance under the 2018 LTIP by 2,000,000 ordinary shares. For Against Abstain Broker Non-Votes 37,967,275 7,308,464 1,464,036 3,199,572”
PROTHENA CORP PUBLIC LTD CO shareholders approved Approval of Compensation of the Company’s Named Executive Officers at the 2023-05-16 meeting.
“Proposal No. 3: Approval of Compensation of the Company’s Named Executive Officers. The shareholders approved, in a non-binding advisory vote, the compensation of the Company’s executive officers named in the Proxy Statement. For Against Abstain Broker Non-Votes 45,196,711 358,628 1,184,436 3,199,572”
PROTHENA CORP PUBLIC LTD CO shareholders approved Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm for 2023 and Authorization of the Board of Directors to Approve the Remuneration of that Auditor at the 2023-05-16 meeting.
“Proposal No. 2: Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm for 2023 and Authorization of the Board of Directors to Approve the Remuneration of that Auditor. The shareholders ratified, in a non-binding vote, the appointment of KPMG LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023, and authorized, in a binding vote, the Company’s Board of Directors, acting through its Audit Committee, to approve the remuneration of that auditor. For Against Abstain 49,873,279 64,757 1,311”
PROTHENA CORP PUBLIC LTD CO shareholders approved Election of Directors at the 2023-05-16 meeting.
“The shareholders re-elected the following individuals to the Company’s Board of Directors to hold office until no later than the annual general meeting of shareholders in 2026. Nominee For Against Abstain Broker Non-Votes Helen S. Kim 46,679,519 57,113 3,143 3,199,572 Gene G. Kinney 46,523,477 213,725 2,573 3,199,572 Oleg Nodelman 35,242,673 11,493,863 3,239 3,199,572 Dennis J. Selkoe 46,506,731 230,399 2,645 3,199,572”
William H. Dunn, Jr., M.D. was appointed as Director at PROTHENA CORP PUBLIC LTD CO.
“On May 16, 2023, the Board of Directors (the “Board”) of Prothena Corporation plc (the “Company”) increased the size of the Board and appointed William H. Dunn, Jr., M.D. to serve as a director of the Company, effective immediately.”
PROTHENA CORP PUBLIC LTD CO reported first quarter of 2023 results: net income $46.9 million.
“For the first quarter of 2023, Prothena reported net loss of $46.9 million”
Sanjiv K. Patel resigned as Director at PROTHENA CORP PUBLIC LTD CO.
“On April 25, 2023, Dr. Sanjiv K. Patel notified Prothena Corporation plc (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”) and as a member of the Compensation Committee of the Board, effective as of July 1, 2023.”
PROTHENA CORP PUBLIC LTD CO reported third quarter ended September 30, 2022 results: revenue $1.5 million, net income net loss of $45.8 million, EPS $0.97.
“For the third quarter and first nine months of 2022, Prothena reported a net loss of $45.8 million and $123.3 million, respectively, as compared to a net income o f $109.2 million and $100.2 million for the third quarter and first nine months of 2021, respectively. Net loss per share for the third quarter of 2022 and first nine months of 2022 was $0.97, and $2.63, respectively, a s compared to net income per share on a diluted basis of $2.13 and $2.12 f or the third quarter and first nine months of 2021, respectively. Prothena reported total revenue of $1.5 million and $4.0 million for the third quarter and first nine months of 2022, respectively, primarily from collaboration revenue from BMS.”
PROTHENA CORP PUBLIC LTD CO entered into Sublease with Arcus Biosciences, Inc. valued at approximately $9,347,100.00 (effective 2022-10-28).
“On October 28, 2022, Prothena Biosciences Inc (“PBI”), a wholly owned subsidiary of Prothena Corporation plc (the “Company”), entered into a Sublease (the “Sublease”) with Arcus Biosciences, Inc., a Delaware corporation (“Sublandlord”), to sublease approximately 31,157 square feet of office and laboratory space located at 1800 Sierra Point Parkway, Brisbane, California (the “New Facility”).”
Brandon S. Smith was appointed as Chief Operating Officer at PROTHENA CORP PUBLIC LTD CO.
“Brandon S. Smith to replace Mr. Nguyen as the Company’s Chief Operating Officer”
Tran B. Nguyen was appointed as Chief Strategy Officer at PROTHENA CORP PUBLIC LTD CO.
“appointed Tran B. Nguyen to the additional and newly created role of the Company’s Chief Strategy Officer”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.